BioStem director gains 7,671 shares via RSUs

BioStem Technologies, Inc. (BSEM) reported that director Mark A. Glickman had 7,671 Restricted Stock Units vest on August 27, 2026.

Rhea-AI Filing Summary

BioStem Technologies, Inc. (BSEM) reported that director Mark A. Glickman had 7,671 Restricted Stock Units vest on August 27, 2026. These RSUs were exercised and converted into 7,671 shares of common stock at a reported price of $0.00 per share, reflecting a stock-based compensation event rather than an open-market trade. Following the transactions, Glickman holds 7,671 shares of common stock directly and no remaining RSUs from this grant.

Insider Trade Summary

7,671 shares exercised/converted

Exercise 2 txns

Insider Glickman Mark A

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F1, F2	7,671	$0.00	$0.00
Exercise	Common Stock	7,671	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 7,671 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
2. F2. These restricted stock units vested on August 27, 2026.

Key Figures

Restricted Stock Units exercised: 7,671 units Common stock acquired: 7,671 shares Exercise price per share: $0.00 per share +2 more

5 metrics

Restricted Stock Units exercised 7,671 units RSUs converted into common stock on August 27, 2026

Common stock acquired 7,671 shares Shares received from RSU exercise on August 27, 2026

Exercise price per share $0.00 per share Reported for the RSU conversion into common stock

Common stock holdings after transaction 7,671 shares Direct holdings of Mark A. Glickman following the Form 4 transactions

RSU vesting date August 27, 2026 Date on which the Restricted Stock Units vested

Key Terms

Restricted Stock Units, derivative security, acquired/disposed code

3 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

acquired/disposed code financial

"transaction_direction_source: acquired_disposed_code"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BSEM director Mark A. Glickman report?

Mark A. Glickman reported the vesting and exercise of 7,671 Restricted Stock Units into 7,671 shares of BioStem Technologies common stock on August 27, 2026, at a reported price of $0.00 per share as part of his equity compensation.

How many BioStem Technologies (BSEM) RSUs vested for Mark A. Glickman?

A total of 7,671 Restricted Stock Units vested for director Mark A. Glickman on August 27, 2026, with each RSU representing a contingent right to receive one share of BioStem Technologies’ common stock.

How many BSEM common shares did Mark A. Glickman acquire in this Form 4?

Mark A. Glickman acquired 7,671 shares of common stock of BioStem Technologies through the exercise and conversion of an equal number of Restricted Stock Units on August 27, 2026.

What is Mark A. Glickman’s BioStem Technologies (BSEM) holding after this transaction?

After the reported transactions, Mark A. Glickman directly holds 7,671 shares of BioStem Technologies common stock, and the specific RSU award exercised in this filing has a remaining balance of 0 units.

Were there any open-market buys or sells in this BSEM Form 4?

No. The Form 4 for BioStem Technologies reports an exercise/conversion of 7,671 Restricted Stock Units into common stock at a reported price of $0.00 per share, with no open-market purchase or sale transactions disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:16 PM EDT Accepted by SEC EDGAR 08/28/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glickman Mark A

(Last) (First) (Middle)

C/O BIOSTEM TECHNOLOGIES, INC.

2836 CENTER PORT CIRCLE

(Street)

POMPANO BEACH FLORIDA 33064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioStem Technologies, Inc. [ BSEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2026		M		7,671	A	$0.00	7,671	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	08/27/2026		M			7,671	(2)	(2)	Common Stock	7,671	$0.00	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. These restricted stock units vested on August 27, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Katherine Gorrell, Attorney-in-Fact	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)